Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study

被引：0
|
作者：
Haifer, C. [1 ,2 ]
Srinivasan, A. [3 ,4 ]
Menon, S. [5 ]
An, Y. [9 ]
Picardo, S. [8 ]
Van Langenberg, D.
Begun, J. [8 ,9 ]
Ghaly, S. [1 ]
Thin, L. [6 ,7 ]
机构：
[1] St Vincents Hosp, Melbourne, Vic, Australia
[2] Univ Sydney, Sydney, NSW, Australia
[3] Eastern Hlth, Box Hill, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Royal Perth Hosp, Perth, WA, Australia
[6] Fiona Stanley Hosp, Murdoch, WA, Australia
[7] Univ Western Australia, Perth, WA, Australia
[8] Mater Hosp, Brisbane, Qld, Australia
[9] Univ Queensland, Brisbane, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
217
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Nonmedical Switching From Infliximab Originator to Infliximab Biosimilar CT-P13 in Patients With Inflammatory Bowel Disease, A Single-Center Prospective Study in Japan
    Takeda, Teruyuki
    Takahashi, Atsushi
    Mikumo, Hiroyuki
    Kinjo, Ken
    Yasukawa, Shigeyoshi
    Koga, Akihiro
    Takatsu, Noritaka
    Hisabe, Takashi
    Arima, Hisatomi
    Imakiire, Sou
    Yamauchi, Eri
    Yao, Kenshi
    Hirai, Fumihito
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S11 - S11
  • [42] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar
    Sudheer K. Vuyyuru
    Bhaskar Kante
    Saurabh Kedia
    Pabitra Sahu
    Mukesh Kumar Ranjan
    Sandeep Mundhra
    Rithvik Golla
    Mukesh Kumar
    Shubi Virmani
    Anvita Gupta
    Nidhi Yadav
    Govind Makharia
    Vineet Ahuja
    Indian Journal of Gastroenterology, 2022, 41 : 446 - 455
  • [43] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Kumar, Peeyush
    Vuyyuru, Sudheer K.
    Kante, Bhaskar
    Kedia, Saurabh
    Sahu, Pabitra
    Ranjan, Mukesh Kumar
    Mundhra, Sandeep
    Golla, Rithvik
    Kumar, Mukesh
    Virmani, Shubi
    Gupta, Anvita
    Yadav, Nidhi
    Makharia, Govind
    Ahuja, Vineet
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (05) : 446 - 455
  • [44] EFFICACY AND SAFETY OF SWITCHING FROM REFERENCE INFLIXIMAB TO BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: FIRST FRENCH EXPERIENCE
    Soret, Pierre-Antoine
    Prieux-Klotz, Caroline
    Avouac, Jerome
    Molto, Anna
    Dior, Marie
    Brieau, Bertrand
    Dreanic, Johann
    Camus, Marine
    Barret, Maximilien
    Coriat, Romain
    Conort, Ornella
    Chast, FranOois
    Goulvestre, Claire
    Le Jeunne, Claire
    Dougados, Maxime
    Nahon, Stephane
    Chaussade, Stanislas
    Abitbol, Vered
    GASTROENTEROLOGY, 2017, 152 (05) : S402 - S402
  • [45] Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience
    Soret, P. -A.
    Prieux-Klotz, C.
    Avouac, J.
    Molto, A.
    Dior, M.
    Brieau, B.
    Dreanic, J.
    Camus, M.
    Barret, M.
    Coriat, R.
    Conort, O.
    Chast, F.
    Goulvestre, C.
    Le Jeunne, C.
    Dougados, M.
    Nahon, S.
    Chaussade, S.
    Abitbol, V.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S318 - S319
  • [46] Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
    Fischer, Sarah
    Cohnen, Sarah
    Klenske, Entcho
    Schmitt, Heike
    Vitali, Francesco
    Hirschmann, Simon
    Ramming, Andreas
    Zundler, Sebastian
    Rath, Timo
    Krebs, Sabine
    Dorje, Frank
    Uter, Wolfgang
    Nagore, Daniel
    Meyer, Sebastian
    Neurath, Markus F.
    Atreya, Raja
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [47] Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease
    Huoponen, S.
    Eberl, A.
    Rasanen, P.
    Roine, R. P.
    Sipponen, T.
    Arkkila, P.
    Blom, M.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S430 - S430
  • [48] Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
    Mahmmod, Shaden
    Schultheiss, Johannes P. D.
    van Bodegraven, Ad A.
    Dijkstra, Gerard
    Gilissen, Lennard P. L.
    Hoentjen, Frank
    Lutgens, Maurice W. M. D.
    Mahmmod, Nofel
    Van der Meulen-de Jong, Andrea E.
    Smits, Lisa J. T.
    Tan, Adriaan C. I. T. L.
    Oldenburg, Bas
    Fidder, Herma H.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 1954 - 1962
  • [49] Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
    Massimi, Davide
    Barberio, Brigida
    Bertani, Lorenzo
    Costa, Francesco
    Ferronato, Antonio
    Facchin, Sonia
    Cardin, Romilda
    Cingolani, Linda
    Casadei, Cesare
    D'Inca, Renata
    Zingone, Fabiana
    Savarino, Edoardo Vincenzo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [50] Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease
    Binkhorst, Lisette
    Sobels, Annemieke
    Stuyt, Rogier
    Westerman, Elsbeth M.
    West, Rachel L.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (07) : 699 - 703
12345